Process for preparing lentinan drip liquid

Abstract

The preparation process of lentinan drip liquid includes the following steps: dissolving lentinan powder into NaOH solution of 0.290-0.323 mol / L concentration via stirring to form lentinan-NaOH solution with 1 mg lentinan in 50 ml of NaOH solution, adding HCl solution in the same concentration as NaOH solution via stirring to prepare lentinan-NaCl solution, measuring pH value and adding NaOH or HCl to regulate pH value to 5.5-7.0, filtering, canning and sealing, sterilizing, inspection and packing. The lentinan drip liquid may be clinically used conveniently without secondary pollution.

Description

1. Technical field [0001] The invention relates to a method for preparing a pharmaceutical dosage form, in particular to a method for preparing a lentinan infusion solution. 2. Background technology [0002] Lentinan is a new drug that has been used clinically in recent years. It has strong anti-tumor activity against gastric cancer and liver cancer, can improve the body immunity of patients, and prevent and treat headaches, vomiting and other unsuitable symptoms caused by radiotherapy. Since the maximum solubility of lentinan in water is only 3mg / ml, and it is easy to precipitate in a gel form when placed at a lower temperature for a long time, so at present, there are not many directly dissolving lentinan in water to make an infusion solution according to the common method, and most By adding sodium citrate as a co-solvent to make 2ml water injection, a few made into powder injection. In clinical application, although the water injection can be injected intravenously, it ...

AI Technical Summary

Problems solved by technology

[0003] Because the lentinan infusion solution prepared according to the common method is easy to separate out jelly, which affects the quality of the drug, so there is no lentinan infusion solution formulation at present; the powder injection is not only expensive to manufacture, but it needs to be made into an infusion solution for clinical application. It is inconvenient to use, and the dextran or mannitol added as a cosolvent may also produce side effects; the sodium citrate added as a cosolvent in the water injection has limitations in clinical use because of its anticoagulant effect, and it is added to the large infusion The operation process is likely to cause secondary pollution